PRL and neoplasm: Pharmacological resistance of PRL-secreting tumors is generally defined as failure to normalize PRL levels, and to achieve tumor size reduction of at least 50%, although this definition is still controversial and a variety of definitions of DA-resistance have been used (15, 18).